BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25209969)

  • 1. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.
    Dobbin ZC; Katre AA; Steg AD; Erickson BK; Shah MM; Alvarez RD; Conner MG; Schneider D; Chen D; Landen CN
    Oncotarget; 2014 Sep; 5(18):8750-64. PubMed ID: 25209969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Profiles Associated with Chemoresistance in Patient-Derived Xenograft Models of Ovarian Cancer.
    Li LY; Kim HJ; Park SA; Lee SH; Kim LK; Lee JY; Kim S; Kim YT; Kim SW; Nam EJ
    Cancer Res Treat; 2019 Jul; 51(3):1117-1127. PubMed ID: 30428638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth inhibition of ovarian tumor-initiating cells by niclosamide.
    Yo YT; Lin YW; Wang YC; Balch C; Huang RL; Chan MW; Sytwu HK; Chen CK; Chang CC; Nephew KP; Huang T; Yu MH; Lai HC
    Mol Cancer Ther; 2012 Aug; 11(8):1703-12. PubMed ID: 22576131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
    Raghavan S; Mehta P; Ward MR; Bregenzer ME; Fleck EMA; Tan L; McLean K; Buckanovich RJ; Mehta G
    Clin Cancer Res; 2017 Nov; 23(22):6934-6945. PubMed ID: 28814433
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors.
    Alvero AB; Montagna MK; Sumi NJ; Joo WD; Graham E; Mor G
    Oncotarget; 2014 Sep; 5(18):8703-15. PubMed ID: 25237928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
    Glaser G; Weroha SJ; Becker MA; Hou X; Enderica-Gonzalez S; Harrington SC; Haluska P
    PLoS One; 2015; 10(5):e0126867. PubMed ID: 25962155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
    Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
    Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
    Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
    Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
    Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
    Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
    BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated genomics of ovarian xenograft tumor progression and chemotherapy response.
    Stuckey A; Fischer A; Miller DH; Hillenmeyer S; Kim KK; Ritz A; Singh RK; Raphael BJ; Brard L; Brodsky AS
    BMC Cancer; 2011 Jul; 11():308. PubMed ID: 21781307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.
    Abubaker K; Latifi A; Luwor R; Nazaretian S; Zhu H; Quinn MA; Thompson EW; Findlay JK; Ahmed N
    Mol Cancer; 2013 Mar; 12():24. PubMed ID: 23537295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
    Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
    Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature.
    Roy L; Samyesudhas SJ; Carrasco M; Li J; Joseph S; Dahl R; Cowden Dahl KD
    Oncotarget; 2014 Sep; 5(18):8355-66. PubMed ID: 25327563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer.
    Cornelison R; Dobbin ZC; Katre AA; Jeong DH; Zhang Y; Chen D; Petrova Y; Llaneza DC; Steg AD; Parsons L; Schneider DA; Landen CN
    Clin Cancer Res; 2017 Nov; 23(21):6529-6540. PubMed ID: 28778862
    [No Abstract]   [Full Text] [Related]  

  • 18. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
    Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.
    Matossian MD; Burks HE; Elliott S; Hoang VT; Bowles AC; Sabol RA; Wahba B; Anbalagan M; Rowan B; Abazeed ME; Bunnell BA; Moroz K; Miele L; Rhodes LV; Jones SD; Martin EC; Collins-Burow BM; Burow ME
    BMC Cancer; 2019 Mar; 19(1):205. PubMed ID: 30845999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts.
    Palmer AC; Plana D; Gao H; Korn JM; Yang G; Green J; Zhang X; Velazquez R; McLaughlin ME; Ruddy DA; Kowal C; Muszynski J; Bullock C; Rivera S; Rakiec DP; Elliott G; Fordjour P; Meyer R; Loo A; Kurth E; Engelman JA; Bitter H; Sellers WR; Williams JA; Sorger PK
    Cancer Res; 2020 Oct; 80(19):4278-4287. PubMed ID: 32747364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.